AxoGen, Inc. (NASDAQ:AXGN) Director Jamie Mark Grooms sold 38,405 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $26.35, for a total transaction of $1,011,971.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jamie Mark Grooms also recently made the following trade(s):

  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The shares were sold at an average price of $26.22, for a total transaction of $558,223.80.
  • On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The shares were sold at an average price of $26.38, for a total transaction of $2,223,702.10.

AxoGen, Inc. (NASDAQ AXGN) traded up $0.40 on Wednesday, hitting $26.60. 286,953 shares of the stock were exchanged, compared to its average volume of 217,276. AxoGen, Inc. has a 12 month low of $8.35 and a 12 month high of $27.60. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $16.05 million for the quarter, compared to analyst estimates of $15.55 million. AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business’s quarterly revenue was up 43.2% compared to the same quarter last year. equities research analysts predict that AxoGen, Inc. will post -0.31 EPS for the current fiscal year.

AXGN has been the topic of several research reports. Roth Capital restated a “buy” rating and issued a $21.00 price target (up previously from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. Leerink Swann lifted their price objective on shares of AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, November 21st. Lake Street Capital lifted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Wedbush reiterated a “buy” rating and set a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Finally, Jefferies Group began coverage on shares of AxoGen in a research note on Thursday, November 30th. They set a “buy” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $26.17.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of AxoGen by 9.0% during the second quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after purchasing an additional 101,245 shares during the period. Bank of New York Mellon Corp increased its stake in shares of AxoGen by 293.9% in the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock worth $12,222,000 after buying an additional 471,209 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock worth $10,245,000 after buying an additional 431,057 shares during the last quarter. State Street Corp increased its stake in shares of AxoGen by 19.6% in the second quarter. State Street Corp now owns 438,641 shares of the medical equipment provider’s stock worth $7,350,000 after buying an additional 71,752 shares during the last quarter. Finally, Castleark Management LLC bought a new stake in shares of AxoGen in the second quarter worth $5,426,000. Institutional investors own 66.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AxoGen, Inc. (AXGN) Director Sells $1,011,971.75 in Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/13/axogen-inc-axgn-director-sells-1011971-75-in-stock.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.